Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Australian Biotech Hopes Nasal Spray Can Alter Course Of COVID-19 Spread

COPD Among Other Potential Areas

Executive Summary

ENA Respiratory expects its "preventive" nasal spray, which primes innate immunity against respiratory viruses including SARS-CoV-2, to play a meaningful role in protecting at-risk populations and lowering community transmission of COVID-19. It plans to explore the potential of the broad-spectrum antiviral immunomodulator in other areas, including COPD, and wider partnering opportunities.

You may also be interested in...



Asia Deal Watch: Hansoh Teams Up With OliX On SIRNA Therapies

Among other Asia deals, Takeda adds to pair of recent gene therapy tie-ups with a CNS-focused cell therapy partnership with Immusoft; earlier it licensed ex-US rights to JCR’s Hunter syndrome drug.

Deciphering Molnupiravir’s India Trial Discontinuation In Moderate COVID-19

Two Indian firms want to terminate specific Phase III trials for molnupiravir, the Merck/ Ridgeback Biotherapeutics’ antiviral in the spotlight as a treatment for mild-to-moderate COVID-19. Should much be read into these plans or is it merely an “administrative closure” that is being sought?

Ex-Amgen CIO McKenzie: 'We All Have To Think Like Software Companies'

Amgen’s former chief information officer Diana McKenzie highlights the inroads made by technology firms in health care and how life science companies can adapt from them while leveraging core capabilities at scale.

Topics

Related Companies

UsernamePublicRestriction

Register

SC145202

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel